Home > Boards > Free Zone > Health and Sciences > Biotech Values

>AVEOwhether they would rather focus on other indications

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biomaven0 Member Profile
Member Level 
Followed By 62
Posts 3,655
Boards Moderated 0
Alias Born 02/27/07
160x600 placeholder
U.S. Stocks: Futures Up With Eyes On Ford, Facebook
Stock futures rose ahead of earnings from Ford Motor Co. and Caterpillar Inc. on Thursday, with investors inspired after Facebook busted through Wall Street's expectations.
Top Equities Stories Of The Day
U.N. Body to Widen Flight Warnings
European Stocks Slip; Shire Leads FTSE Gains
Have Big-Screen Smartphones Crashed the Tablet Party?
Nokia Swings to Second Quarter Profit
U.S. Hot Stocks: Hot Stocks to Watch
Correction to Facebook Earnings Story, Market Talk
Allergan to Lay Off 13% of Workforce, Cut Drug Research -- 3rd Update
Judge Delays Decision on Argentine Bonds
biomaven0 Member Level  Thursday, 09/08/11 09:41:43 AM
Re: NP1986 post# 126293
Post # of 180676 
>AVEO

Quote:
whether they would rather focus on other indications



My guess is they will try to go for combination therapy - any place where Avastin has shown good results in combination would be a good place to start.

In terms of going up against Sutent vs. against Nexavar, it's somewhat instructive that Pfizer made the same choice in 2nd line for their drug. I'm of the view that a small company should almost always take the easiest path to registration - worry about expanding the market once you have approval.

Peter

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist